Tag: Pharmaceuticals

Key Updates in U.S. Healthcare Regulations and Innovations

Explore critical updates in U.S. healthcare regulations, insurance market dynamics, and innovations in patient care including AI and new billing practices

New CMS Guidance on Medicare Drug Pricing Initiatives

Discover CMS's draft guidance on Medicare drug pricing, impacting stakeholders and beneficiaries, designed to streamline processes and enhance compliance.

Johnson & Johnson's Second Quarter Performance: Medical Device Insights

Explore Johnson & Johnson's second quarter performance and insights on medical device sales, market dynamics and the impact of healthcare demand.

Significant Progress in Combating Healthcare Fraud by HHS OIG

Learn about HHS OIG's progress in combating healthcare fraud, major actions, and legislative developments addressing Medicaid and Medicare spending.

Tonix Pharmaceuticals Expands Medicare Coverage for TONMYA®

Tonix Pharmaceuticals expands Medicare coverage for TONMYA®, improving access for 9M beneficiaries. Discover innovations in fibromyalgia treatments.

Medicare GLP-1 Bridge Program Enhances Access to Weight Loss Medications

Discover how the new Medicare GLP-1 Bridge program improves access to weight loss medications for millions of Americans. Learn more about eligibility and benefits.

Major 2026 Medicare and FDA Regulatory Changes Impacting Healthcare

Discover critical 2026 regulatory changes by CMS and FDA that will impact reimbursement, prescribing practices, and patient care throughout healthcare specialties.

Rising Use of GLP-1 Medications and the Medicare GLP-1 Bridge Initiative

Explore the surge in GLP-1 medication use and the Medicare Bridge program enabling easier access for eligible individuals in weight management.

Medicare GLP-1 Bridge Program: Weight Management for Medicare Beneficiaries

Discover the CMS Medicare GLP-1 Bridge program supporting weight management for beneficiaries—access effective treatments at an affordable cost.

Lower Medicare Costs for GLP-1 Medications: Impact and Implications

New Medicare initiative reduces copayments for GLP-1 medications, enhancing affordability and potentially lowering overall healthcare costs for beneficiaries.